S-15535: Difference between revisions
Appearance
Content deleted Content added
Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report errors or bugs) |
m Infobox drug: rm/replace deprecated params. Fix unk parameters (rm some Chembox-params) (via AWB script) |
||
Line 4: | Line 4: | ||
| IUPAC_name = 1-(2,3-dihydro-1,4-benzodioxin-8-yl)-4-(2,3-dihydro-1''H''-inden-2-yl)piperazine |
| IUPAC_name = 1-(2,3-dihydro-1,4-benzodioxin-8-yl)-4-(2,3-dihydro-1''H''-inden-2-yl)piperazine |
||
| image = S-15535_structure.png |
| image = S-15535_structure.png |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
Line 10: | Line 9: | ||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| bioavailability = |
| bioavailability = |
||
Line 16: | Line 14: | ||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
Line 26: | Line 23: | ||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
||
| ChEMBL = 49247 |
| ChEMBL = 49247 |
||
| |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = 117196 |
| ChemSpiderID = 117196 |
||
| |
| MeSHName = C079549 |
||
| MeSHName = C079549 |
|||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=21 | H=24 | N=2 | O=2 |
| C=21 | H=24 | N=2 | O=2 |
||
| molecular_weight = 336.427 g/mol |
| molecular_weight = 336.427 g/mol |
||
| smiles = C1CN(CCN1C2CC3=CC=CC=C3C2)C4=C5C(=CC=C4)OCCO5 |
| smiles = C1CN(CCN1C2CC3=CC=CC=C3C2)C4=C5C(=CC=C4)OCCO5 |
||
| |
| InChI = 1/C21H24N2O2/c1-2-5-17-15-18(14-16(17)4-1)22-8-10-23(11-9-22)19-6-3-7-20-21(19)25-13-12-24-20/h1-7,18H,8-15H2 |
||
| |
| InChIKey = QJPPEMXOOWNICQ-UHFFFAOYAE |
||
| |
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
||
| StdInChI = 1S/C21H24N2O2/c1-2-5-17-15-18(14-16(17)4-1)22-8-10-23(11-9-22)19-6-3-7-20-21(19)25-13-12-24-20/h1-7,18H,8-15H2 |
| StdInChI = 1S/C21H24N2O2/c1-2-5-17-15-18(14-16(17)4-1)22-8-10-23(11-9-22)19-6-3-7-20-21(19)25-13-12-24-20/h1-7,18H,8-15H2 |
||
| |
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
||
| StdInChIKey = QJPPEMXOOWNICQ-UHFFFAOYSA-N |
| StdInChIKey = QJPPEMXOOWNICQ-UHFFFAOYSA-N |
||
}} |
}} |
Revision as of 13:36, 28 June 2015
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.150.279 |
Chemical and physical data | |
Formula | C21H24N2O2 |
Molar mass | 336.427 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
S-15535 is a phenylpiperazine drug which is a potent and highly selective 5-HT1A receptor ligand that acts as an agonist and antagonist (weak partial agonist) at the presynaptic and postsynaptic 5-HT1A receptors, respectively.[1][2][3][4] It has anxiolytic properties.[4][5]
See also
References
- ^ Millan MJ, Rivet JM, Canton H, Lejeune F, Gobert A, Widdowson P, Bervoets K, Brocco M, Peglion JL. (1993). "S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist (weak partial agonist) at presynaptic and postsynaptic sites respectively". Eur J Pharmacol. 230 (1): 99–102. doi:10.1016/0014-2999(93)90416-F. PMID 8381359.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Millan MJ, Canton H, Gobert A, Lejeune F, Rivet JM, Bervoets K, Brocco M, Widdowson P, Mennini T, Audinot V; et al. (1994). "Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists". J Pharmacol Exp Ther. 268 (1): 337–352. PMID 8301575.
{{cite journal}}
: Explicit use of et al. in:|author=
(help)CS1 maint: multiple names: authors list (link) - ^ Millan MJ, Newman-Tancredi A, Rivet JM, Brocco M, Lacroix P, Audinot V, Cistarelli L, Gobert A. (1997). "S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity". J Pharmacol Exp Ther. 282 (1): 132–147. PMID 9223549.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ a b Lejeune F, Millan MJ. (1998). "Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535". Synapse. 30 (2): 172–180. doi:10.1002/(SICI)1098-2396(199810)30:2<172::AID-SYN7>3.0.CO;2-9. PMID 9723787.
- ^ Dekeyne A, Brocco M, Adhumeau A, Gobert A, Millan MJ. (2000). "The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents". Psychopharmacology (Berl). 152 (1): 55–66. doi:10.1007/s002130000449. PMID 11041316.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)